The Covid crash continues
Pfizer keeps declining, but it is not the only pandemic player to suffer.
Key second-quarter clinical readouts for pharma
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.